Shenzhen Stock Exchange Issued Supervision Letter To Dezhan Health (000813. SZ), And The Accounting Treatment Of Its Subsidiaries Was Not Standardized

On December 20, Shenzhen Stock Exchange issued a supervision letter to Dezhan health (000813. SZ). According to the investigation, from 2017 to 2019, the accounting treatment of sales discount, sales return and product promotion fee of Beijing Jialin Pharmaceutical Co., Ltd., a subsidiary of Dechan health, was not standardized. For example, 28.1037 million yuan of sales discount was mistakenly recorded into the product promotion fee in 2017, and 22.6499 million yuan in 2019 was mistakenly included in the sales promotion fee of previous years. These acts constitute violations. In this regard, Shenzhen stock exchange requires the board of directors of Dezhan health to pay full attention to the above problems and rectify them in time to prevent the recurrence of the above problems.